Iolyx Therapeutics

aid: iolyx-therapeutics
name: Iolyx Therapeutics
description: 'Iolyx Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Burlingame,
  California, working at what it calls the intersection of immunology and ophthalmology — "immuno-ophthalmology". The company
  develops immunomodulatory therapeutics that target ocular inflammation at its source, using what it describes as innovative
  pathways and tailored formulations for precise delivery to the relevant ocular tissues, positioned as an alternative to
  conventional steroids and broad immunosuppressants. Its lead asset, ILYX-002, is in trials for autoimmune-associated dry
  eye disease; the company announced Phase 2 results in May 2025 and, in December 2025, a strategic agreement with Laboratoires
  Théa to develop and commercialize ILYX-002 alongside Series B funding for its retinal pipeline. The stated pipeline spans
  front-of-eye indications (dry eye, ocular allergy, rosacea, uveitis) and back-of-eye indications (age-related macular degeneration,
  diabetic retinopathy, posterior uveitis). Iolyx is a drug developer rather than a software vendor: it operates a six-page
  WordPress marketing site at iolyx.com and publishes no public API, developer portal, SDK, or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/iolyx-therapeutics/refs/heads/main/apis.yml
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://iolyx.com/wp-content/uploads/2023/10/iolyx-logo.png
x-type: company
x-source: harvest:secondary-market
x-harvest-listing: https://www.nasdaqprivatemarket.com/
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-10-06'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Ophthalmology
- Immunology
- Clinical Trials
tags_raw:
- Company
- Health Care
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Ophthalmology
- Immunology
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- url: https://iolyx.com/news/
  type: Blog
- type: DomainSecurity
  url: security/iolyx-therapeutics-domain-security.yml
- type: Website
  url: https://iolyx.com/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Iolyx is a clinical-stage drug developer whose entire web presence is a six-page WordPress marketing site (Home,
    Pipeline, Team, News, Media, Contact) with zero blog posts, no developer or API section, no GitHub organization, and no
    package on any public registry — the only machine-readable thing on iolyx.com is the stock WordPress /wp-json/ discovery
    document the hosting stack serves by default, which is not a product API.
  evidence:
  - url: https://iolyx.com/
    status: 200
  - url: https://iolyx.com/openapi.json
    status: 404
  - url: https://iolyx.com/llms.txt
    status: 404
  - url: https://iolyx.com/.well-known/agent-card.json
    status: 404
  - url: https://iolyx.com/wp-json/
    status: 200
  - url: https://api.github.com/orgs/iolyx-therapeutics
    status: 404
  checked: '2026-08-23'